Background. Cytomegalovirus (CMV) D+/R− solid-organ transplant (SOT) recipients carry
increased risk of developing CMV disease; however, other risk factors in these patients have …

Background The attack rate of cytomegalovirus (CMV) is over 50% in solid organ transplant
recipients at risk for primary CMV infection and in those receiving antilymphocyte antibody …

Late‐onset cytomegalovirus (CMV) disease is a significant problem with a standard 3‐month
prophylaxis regimen. This multicentre, double‐blind, randomized controlled trial compared …

Background The main challenge with cytomegalovirus (CMV) prophylaxis in IgG donor-
positive/recipient-negative (D+/R–) kidney transplant recipients is late-onset CMV disease …

We prospectively followed 70 CMV-seropositive solid organ transplant recipients to evaluate
the efficacy and safety of valganciclovir (VGCV) as preemptive therapy based on …

Optimal measures for the prevention of cytomegalovirus (CMV) in high‐risk orthotopic liver
transplant (OLT) patients are unknown. The charts of high‐risk OLT recipients with 12 …

Background. Cytomegalovirus (CMV) prevention can be achieved by prophylaxis or
preemptive therapy. We performed a prospective randomized trial to determine whether …

Renal transplant recipients (RTR) who are seropositive for CMV (R+) are considered to be at
intermediate risk for CMV disease. Current guidelines recommend high‐dose valganciclovir …

Prophylaxis reduces cytomegalovirus (CMV) disease, but is associated with increased costs
and risks for side effects, viral resistance and late onset CMV disease. Preemptive therapy …

Cytomegalovirus (CMV)-seronegative liver transplant recipients with CMV-seropositive
donors have the greatest risk for CMV disease. We performed a randomized, controlled trial …